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Background: The use of high-dose chemotherapy combined with autologous stem cell transplantation has
improved the outcome of hematologic malignancies. Nevertheless, this treatment can cause persistent fatigue and
a reduced global quality of life, role and physical function. Physical exercise interventions may be beneficial for
physical fitness, fatigue and quality of life. However, the trials conducted so far to test the effects of physical
exercise interventions in this group of patients were of poor to moderate methodological quality and economic
evaluations are lacking. Hence there is need for a rigorous, appropriately controlled assessment of the effectiveness
of exercise programs in these patients. The aims of the present study are (1) to determine the effectiveness of an
individualized high intensity strength and interval training program with respect to physiological and psychological
health status in patients with multiple myeloma or (non-)Hodgkin’s lymphoma who have recently undergone high
dose chemotherapy followed by autologous stem cell transplantation; and (2) to evaluate the cost-effectiveness of
this program.
Methods: A multicenter, prospective, single blind randomized controlled trial will be performed. We aim to recruit
120 patients within an inclusion period of 2 years at 7 hospitals in the Netherlands. The patients will be randomly
assigned to one of two groups: (1) intervention plus usual care; or (2) usual care. The intervention consists of an
18-week individualized supervised high-intensity exercise program and counselling. The primary outcomes
(cardiorespiratory fitness, muscle strength and fatigue) and secondary outcomes are assessed at baseline, at
completion of the intervention and at 12 months follow-up.
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Background
T h eu s eo fh i g h - d o s ec h e m o t h e r a p y( H D C )c o m b i n e d
with autologous stem cell transplantation (ASCT) has
improved the outcome of haematological malignancies
such as multiple myeloma (MM) and (non-)Hodgkin’s
lymphoma (NHL/HL). It has become standard of care in
these diseases in first line and relapse, respectively.
However, this treatment has long term negative side
effects. Symptoms like fatigue [1-7] and dyspnoea
[1,4,5,8] are highly prevalent among ASCT survivors. In
addition, survivors have a reduced global quality of life,
role and physical function when compared to population
n o r m s[ 9 ] .F o ri n s t a n c e ,u pt o6 0 %o ft h ep a t i e n t s
3 years post-transplant had a compromised ability to
engage in activities as carrying a heavy bag and taking a
long walk [10]. 23-56% of the patients were not able to
return to work during the course of the first year after
ASCT [6,11-13].
The persistent fatigue and deficits in health related
quality of life (HRQoL) might reflect a self-perpetuating
condition [14-18]. Cancer, its treatment and the
associated bed rest can lead to poor physical fitness
(a.o. impaired cardiorespiratory function and reduced
muscle strength). As a result, greater effort is required
to fulfil the activities of daily living, and performance of
these activities can induce an abnormally high level of
fatigue. In order to minimize fatigue, patients will limit
physical activities, which will eventually lead to a greater
decline in physical fitness. An exercise intervention
might break this downward sequence [14-18]. Previous
studies have shown that exercise intervention programs
can improve physical fitness, fatigue level and quality of
life among haematological cancer patients
[14,15,17,19-25]. However, based on systematic reviews,
Liu et al. (2009) and Wiskemann & Huber (2008) con-
c l u d et h a tm o r eh i g hq u a l i t yr e s e a r c hi sn e c e s s a r y
[26,27]. In the review of Liu et al. (2009) [26] only three
of the ten included studies were randomized controlled
trials. The overall quality of many studies reviewed was
limited, with shortcomings related to trial design, sam-
ple size, choice of comparison groups, outcome mea-
sures and duration of follow up [26]. Wiskemann &
Huber (2008) reached similar conclusions [27]. Both
reviews show that there is a need for well designed, ran-
domized controlled trials that verify the findings of the
previous trials and can lead to evidence-based
interventions.
In addition to the limited methodological quality, the
trials performed to date were heterogeneous in terms of
the type of exercise interventions studied. Most of the
studies focussed on isolated aerobic exercise during or
after the stem cell transplantation. Resistance exercise
programs and combined training strategies have been
evaluated more rarely [27]. This is somewhat surprising
since muscle atrophy is a common problem in cancer
patients [28-30]. The muscle athrophy is likely to be
even more pronounced in patients undergoing HDC
and ASCT because of the nature of drugs being used
(a.o. high dose glucocorticoids) [16], and because of
the morbidity associated with the neutropenic phase
after ASCT, which often leads to prolonged bed rest. As
considerable evidence suggests that the ability to per-
form physical tasks in daily life is determined by a cer-
tain threshold level of muscular strength [31], it seems
important that exercise interventions not only aim to
improve aerobic capacity but also aim to minimize mus-
cle atrophy or even stimulate muscle hypertrophy.
To our knowledge, there are currently no data on the
cost-effectiveness of exercise intervention programs in
cancer patients. The common inability to return to
work during the course of the first year after ASCT
[6,11-13], the frequent use of health care resources
[32,33] and the reported financial problems by patients
[8,34] show the importance of determining the cost-
effectiveness of exercise intervention programs.
The current study will evaluate an individualized high
intensity strength and interval training program devel-
oped and pilot-tested by De Backer et al. (2007, 2008) at
the Maxima Medical Center (MMC) in Veldhoven, the
Netherlands [35,36]. This program has shown promising
results with respect to rehabilitation of cancer patients
after chemotherapy, but needs to be further explored
and tested in ASCT survivors.
The aims of the current study are (1) to determine the
effectiveness of a state-of-the-art individualized high
intensity strength and interval training program with
respect to physiological and psychological status in
patients with MM, NHL or HL who have recently
undergone HDC followed by ASCT; and (2) to evaluate
the cost-effectiveness of this exercise program.
We hypothesize that this exercise program will lead to
(1) improved physical fitness; (2) lower levels of fatigue;
(3) less mood disturbance; (4) higher levels of daily
activities; (5) improved HRQoL; (6) a higher partial and
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cost-effective when compared to standard care only.
Methods
The EXIST (EXercise Intervention after Stem cell
Transplantation) study is one of four randomised con-
trolled trials included in the Alpe d’HuZes Cancer Reha-
bilitation (A-CaRe) program.
This study consists of a pilot study which is followed
by a multicenter, prospective, single blind randomized
controlled trial (RCT). The protocol of the pilot study
will be similar to the RCT protocol described in this
manuscript, with the exception of the long term follow
up. The aims of this pilot study are to evaluate the feasi-
bility of the intervention and to test the study logistics.
For these aims, the patients will also be interviewed dur-
ing and after completion of the program about: (1) the
perceived efficacy of and satisfaction with the interven-
tion program and (2) the need for changes to the pro-
gram. If necessary fine tuning of the intervention will
take place.
The aim of the RCT is to compare the exercise inter-
vention and usual care with usual care only (Figure 1).
Eligible patients will be randomly assigned to the inter-
vention or control group. In addition to usual care,
patients in the intervention group will take part in an
18-weeks individualized supervised high-intensity exer-
cise program. This program will start 7-14 weeks after
ASCT. Patients in the control group are treated accord-
ing to usual care. The study protocol was approved by
the Medical Ethics Committee of the Academic Medical
Center (METC AMC 10/106).
Study sample
Eligibility criteria are: (1) diagnosed with MM in first
line or with HL/NHL in first relapse and treated with
HDC and ASCT 6 to 12 weeks ago; (2) sufficiently
recovered from the ASCT: Hb > 6.5 mmol/L, WBC >
3.0 × 10
9/L, platelets > 100 × 10
9/L; (3) aged between
18 and 65 years; (4) able to cycle on a bicycle ergometer
with a load of at least 25 Watt; (5) able to walk at least
100 meters independently without crutches/cane(s) or
walking frame; (6) give written informed consent. Exclu-
sion criteria are (1) treatment with autologous-allogeneic
SCT; presence of (2) severe cognitive impairment; (3)
severe emotional instability; (4) extensive osteolytic
lesions with risk of fracture; (5) serious cardiorespiratory
and/or cardiovascular conditions; (6) severe infections;
(7) progression/relapse of the disease; (8) other disabling
comorbidity interfering with the intervention program
or influencing outcome parameters (a.o. having a pace-
maker, epileptic seizures and/or poorly regulated dia-
betes mellitus); (9) insufficient mastery of the Dutch
language.
Recruitment and randomization
Our goal is to recruit 120 patients within an inclusion
period of two years. Recruitment takes place at the
Academic Medical Center (AMC; Amsterdam), Antoni
van Leeuwenhoek Hospital (Amsterdam), Haga Hospi-
tal (Den Haag), Meander Medical Center (Amersfoort),
Onze Lieve Vrouwe Gasthuis (Amsterdam), St. Antonius
Hospital (Nieuwegein) and University Medical Center
Utrecht. All potentially eligible patients are asked to
complete a short screening questionnaire and are
informed about EXIST by their treating haematologist.
This screening questionnaire assesses co-morbidity,
pre-illness lifestyle, current attitudes toward and beliefs
about exercise in general and exercising after ASCT.
These questions are adapted from measures developed
by Courneya and colleagues [37,38] for use in evaluat-
ing exercise in cancer survivors, and are based on
established health behaviour theories, in particular the
Theory of Planned Behaviour [38]. Patients who are
not willing to participate in EXIST are asked for the
reason for non-participation. Patients who are willing
to participate are asked to provide written informed
consent.
After the baseline measurements a randomization will
take place conform a stratified block randomization
method with a block size of 4 and by using a validated
software package [39]. Stratification factors include
transplant center and diagnosis. A member of the
research team will inform the patient of the randomiza-
tion outcome. Study outcomes will be assessed by
blinded professionals and patients will be instructed not
to reveal their group allocation.
Intervention
Besides the usual care, patients in the intervention
group follow an 18-week exercise program similar to
the program developed by De Backer et al. (2007, 2008)
[35,36]. This program consists of high-intensity resis-
tance and interval training. Before the start of the inter-
vention (T = 0) a sports physician screens the patients
and, adapts the program in case of physical limitations.
Training takes place in localp h y s i o t h e r a p yp r a c t i c e s
supervised by physiotherapists. Patients will train on
specialized resistance training equipment and bicycle
ergometers. Furthermore, the physiotherapist will moti-
vate the patient to maintain an active lifestyle. A
detailed training manual will be available. Table 1
presents the structure of the intervention program.
Resistance exercises
The six resistance exercises target the large muscle
groups: (1) vertical row (longissimus, biceps brachii,
rhomboideus); (2) leg press (quadriceps, glutei, gastro-
cnemius); (3) bench press (pectoralis major, triceps); (4)
pull over (pectoralis, triceps brachii, deltoideus,
Persoon et al. BMC Cancer 2010, 10:671
http://www.biomedcentral.com/1471-2407/10/671
Page 3 of 9trapezius); (5) abdominal crunch (rectus abdominis); (6)
lunge (quadriceps, glutei, hamstrings). Indirect one repe-
tition maximum (1-RM) measurements will be per-
formed every four weeks for all six exercises. In the first
12 weeks, resistance exercise consists of two sets of 10
repetitions at 65 to 80% of the 1-RM. From week 12
onwards it comprises more repetitions (20 repetitions
per set) at a lower resistance (35-40%).
Interval training
Before and after the resistance exercises patients cycle
two times eight minutes. To determine the right
resistance a steep ramp test [40-42] is performed every
four weeks. With this test the subject is instructed to
cycle at a speed between 70 and 80 revolutions per min-
ute (RPM), starting at a work load of 25W for 30 sec-
onds. Hereafter the load is increased by 25W every
10 seconds until exhaustion. Maximal short exercise
capacity (the maximal workload; MSEC) is recorded. In
the first eight weeks, blocks of 30 seconds at 65% of the
MSEC will be alternated with blocks of 60 seconds at
30%. From week nine onwards, the duration of the latter
block is reduced to 30 seconds.
Figure 1 Scheme of the study. ASCT: autologous stem cell transplantation.
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A behavioural motivation component is included to
improve compliance and to stimulate physical activity
outside the exercise program in addition to and after
completion of the exercise program. From week 12
onwards patients are encouraged to meet the recom-
mendations made by the American College of Sports
Medicine and the American Heart Association [43]. Spe-
cific program elements include the provision of general
and motivational information, both verbally and via
folders, about physical activity and the desired intensity
of activity based on the Borg Scale rating perceived
exertion [44]. The physiotherapist uses basic counselling
techniques and instruction sheets.
Standard care
Both the patients in the intervention group and the
patients in the control group receive ‘usual care’.I nt h e
Netherlands usual care varies according to doctors’ and
patients’ preferences. Patients in the control group are
allowed to participate in sports or existing rehabilitation
programs. Information on physical activity and exercise
of all patients will be obtained from the physical activity
questionnaire, recordings of the accelerometer and cost-
diaries (see outcome measures).
Study outcomes
All studies within A-CaRe Clinical Research use similar
methodologies and a comparable set of outcome
measures. Figure 2 shows the timing of the assessments.
The physical tests are performed centrally at the AMC
according to a detailed and standardized protocol. The
questionnaires will be filled out at home.
Primary outcomes measures
Cardiorespiratory fitness At rest respiratory function
will be assessed by measuring the forced air expiratory
volume in 1 second (FEV-1), the forced vital capacity
(FVC), inspiratory capacity (IC) and by estimating the
maximal voluntary ventilation (MVV) [45,46].
A maximal exercise test will be performed to assess
cardiorespiratory fitness and potential cardiovascular
and cardiorespiratory limitations. This technique has
been shown to be feasible in cancer survivors [18].
We will follow international guidelines concerning stan-
dardization and interpretation strategies [47]. The maxi-
mal exercise test will be performed on a cycle ergometer
(Lode Corival, Groningen, the Netherlands) under supervi-
sion of a sports physician. A ramp test design will be
applied: after four minutes of unloaded cycling, the load
will be gradually increased until exhaustion or inability to
maintain pedal frequency above 60 RPM. Throughout the
test the ECG, saturation and blood pressure will be moni-
tored and heart rate (HR) and gas exchange variables
(MasterScreen CPX, CareFusion, Hoechberg, Germany)
will be recorded continuously and averaged at 30 seconds
intervals. We will register peak oxygen uptake (peakVO2),
maximal heart rate (peak HR) and mean power output
(peak W). Ventilatory threshold (VT) will be determined
Table 1 Structure of the exercise program
Week Type of training Number of training
sessions
Aims of the training
1-12 Resistance training and interval training
(2 × 8 minutes).
2× per week,
60 minutes.
1. become familiar with exercise program;
2. overcoming the fear of physical activity;
3. improve coordination and muscle hypertrophy and hereby
improving muscle force;
4. increasing aerobic capacity;
5. increasing the pleasure in being physically active.
13-18 Resistance training and interval training
(2 × 8 minutes).
1× per week,
60 minutes.
1. maintain muscle force;
2. improve muscle endurance;
3. improve aerobic capacity.
1, 4, 10, 12,
18, 22
Counseling. 6 sessions of 5 to
15 minutes
1. improve compliance to the exercise intervention;
2. encourage patients to pursue an active lifestyle.
Training: 30 sessions a 60 minutes = 30 hours
Counseling: 6 sessions a 15 minutes = 1.5 hours
Figure 2 Timeline of the study. ASCT: autologous stem cell transplantation; T0: baseline; T1: post treatment; T2: long term follow-up.
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tory exchange ratio (RER) and HR will be used to review
peak exercise. After the start of recovery, the patient will
be asked about his/her exercise-related perceptions using
the Borg Scale of perceived exertion [44].
Muscle strength Upper extremity muscle strength is
assessed using a grip strength dynamometer (Hydraulic
Hand Dynamometer, North Coast Medical Inc., Morgan
Hill, USA), and lower extremity muscle strength with the
30 seconds chair stand test. Maximal handgrip strength
is measured following the standard procedures recom-
mended by the American Society of Hand Therapists
(ASHT) [48]. The mean score attained for each side will
be recorded. The 30 seconds chair stand test has been
demonstrated to be a valid and reliable measure of proxi-
mal lower limb strength in older adults [49]. The subject
is asked to stand upright from a chair with arms crossed
at the wrist and held against the chest, then return to a
fully seated position and repeat the action at his/her fast-
est pace over a 30 seconds period. The number of full
stands within this time period is recorded.
Fatigue Two self-report questionnaires will be used to
assess fatigue: the Multidimensional Fatigue Inventory
(MFI) and the Fatigue Quality List (FQL). The MFI [50]
is a questionnaire consisting of 20 statements for which
the person has to indicate on a 0-5 scale to what extent
the particular statement applies to him or her. This self-
report instrument consists of five subscales based on
different dimensions: general fatigue, physical fatigue,
reduced activity, reduced motivation and mental fatigue.
The patients’ perception and appraisal of experienced
f a t i g u ew i l lb ea s s e s s e dw i t ht h eF Q L[ 5 1 ] .T h eF Q L
consists of 25 adjectives describing the fatigue experi-
ence, organized into four subscales: frustrating, exhaust-
ing, pleasant, and frightening.
Secondary outcomes measures and moderating variables
Secondary outcomes are body composition, bone
mineral density, HRQoL, neuropathy, objective and self
reported physical activity level, mood disturbance, func-
tioning in daily life, return to work and cost from a
social perspective. In addition, clinical data, disease sta-
tus and treatment, sociodemographic characteristics,
adverse events and potential predictors of compliance
and satisfaction with the exercise program will be
recorded. A complete overview of assessments and
instruments are presented in Table 2. A small selection
of these measures is described in detail here.
Objectively assessed level of physical activity The
Actitrainer accelerometer (Actigraph, Fort Walton
Beach, USA) will be used to measure physical activity.
The Actitrainer is able to measure accelerations from
0.05 to 2.00 G. These accelerations are scored in
“counts” per minute. The Actitrainer will be set at
60 seconds and the measurement period will include
five days including at least one weekend day.
Costs from a societal perspective Costs will be mea-
sured from a societal perspective. The following are
being considered in this study: (1) Health care costs: the
costs of oncological care, general practice care and phy-
siotherapy; additional visits to other health care provi-
ders, prescriptions of medication, professional home care
and hospitalization. (2) Patient and family costs: out-
of-pocket expenses (e.g. travel expenses), costs for sports
and sports equipment, and costs of paid and unpaid help.
(3) Costs due to loss of production (absenteeism for
patients with paid jobs and hours of inactivity for patients
without a paid job). These data will be collected though
retrospective cost questionnaires administered on a
monthly basis during the period between T = 0 and T =
1. After T = 1 the cost questionnaires will be adminis-
tered once every three months till T = 2. Health care uti-
lization will be valued using Dutch cost prices [52].
Return to work The following indicators of return to
work will be measured: (1) Time to partial and to full
return to work (meaning number of calendar days
between end of treatment and first day at work), (2) time
to full return to work corrected for partial return to
work, (3) partial and full return of work rate at T = 1 and
T = 2. (4) Details on hours worked per week, nature of
work, and return to a different job will also be recorded.
Adverse Events All adverse events noticed by treating
physicians and/or physiotherapists or mentioned by the
participant will be recorded and monitored. The grading
o fa d v e r s ee v e n t sw i l lb ed o n eu s i n gt h em o s tr e c e n t
version of the NCI Common Terminology Criteria for
Adverse Events, CTCAE version 4. A complete docu-
ment may be downloaded from [53].
Power calculations
The sample size calculations were estimated for our pri-
mary study outcomes using a two-sided a =0 . 0 5a n da
power of 80%. Based on the results of De Backer et al.
(2007, 2008) [35,36] and Hayes et al. (2004) [17], we
expect a between group difference of 7.5 ± 7 ml/kg/min
i nt h ep e a ko x y g e nu p t a k e( p e a k V O 2); 0.2 ± 0.1 kg in
handgrip strength and 3.5 ± 4 points in fatigue (MFI).
We need between 25 and 42 subjects per group to detect
these differences between the intervention and control
group. We expect a drop-out rate of 30%; 15% of the
patients who have undergone autologous SCT for MM,
HL or NHL have an early relapse within six months and
may not be able to complete the study assessments, and
15% may drop out because of other reasons. Conse-
quently, we need to enrol 60 subjects per group.
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Differences in baseline characteristics between interven-
tion and control groups will be tested using independent
t-tests, Mann Whitney U tests and chi-square tests.
Data will be analyzed on an intention-to-treat
basis. Additionally, a per-protocol analysis will be
performed.
Scores on the self-report measures of fatigue, mood
state and health-related quality of life will be calculated
according to published scoring algorithms. Longitudinal
regression analysis will be used to assess differences in
each outcome measure between the intervention and
control group. The two follow-up measurements will be
defined as dependent variable and multi-level analysis
with three levels will be used, (1) transplant center, (2)
time of follow-up measurement (values corresponding
with performance at T = 1 and T = 2), (3) individual.
Regression coefficients indicate differences between
intervention and control group. Regression models will be
adjusted for baseline values, age and gender. Test results
are considered significant for p-values < 0.05. All analyses
will be performed using the statistics program SPSS.
Cost-effectiveness analysis
Both cost-effectiveness and cost-utility analyses will be
performed. The cost-effectiveness ratios will be calculated
by dividing the difference between the mean costs of the
two treatment groups by the difference in the mean effects
of the two treatment groups. This ratio will include the
primary outcome measures of the trial. The cost-utility
ratio will express the additional costs of the intervention
per quality adjusted life year (QALY). Utilities will be mea-
sured using the EuroQol ([54] EQ5D) at baseline, at the
end of the treatment and at twelve months.
Table 2 Assessments and instruments
Outcome measures Instrument
Primary
Cardiorespiratory fitness Maximal exercise test.
Muscle strength Maximum handgrip strength and 30 seconds chair stands test.
Fatigue Multidimensional Fatigue Inventory (MFI) [50] and the Fatigue Quality List (FQL) [51] questionnaires.
Secondary
Body composition and bone
mineral density
DXA-scans
3 [55,56] and physical examination; height, weight, waist and hip circumferences, four skinfolds (biceps,
triceps, suprailiacal and subscapular).
Objective level of physical activity Recordings of the Actitrainer accelerometer (Actigraph, Fort Walton Beach, USA).
Health-related quality of life EORTC Quality of Life Questionnaire C30 (EORTC QLQ-C30) [57], the EORTC Myeloma Module (QLQ-MY20) [58].
Neuropathy
3 EORTC Chemotherapy-induced peripheral neuropathy module (QLQ-CIPN20) [59].
Self reported physical activity PASE questionnaire [60].
Mood disturbance Hospital Anxiety and Depression Scale (HADS) questionnaire [61,62].
Functioning in daily life Impact on Participation and Autonomy (IPA) questionnaire [63].
Return to work Return to work questionnaire.
Cost questionnaires
4 EuroQol (EQ5D) [54] and cost questionnaires.
Other
Sociodemographic data
1 Age, education, marital status, living situation, co-morbidities and life style variables (e.g. smoking).
Medical history
1 Date of diagnosis, subtype of disease, stage of disease, history of therapy will be recorded from medical records.
Disease status and treatment Blood levels (incl. platelet and erythrocyte count), response to treatment, progression or relapse of disease and
data on any additional treatment will be recorded from medical records.
Comorbidity A questionnaire and at T = 0 a sports physician will examine comorbidities that might interfere with the
intervention program or influence study outcome.
Adverse events Medical records, reports of the sports physician and physiotherapist.
Potential predictors of
compliance
Questionnaire about pre-illness lifestyle, current attitudes toward and beliefs about exercise in general.
Satisfaction with the intervention
2 Satisfaction questionnaire; intervention arm only.
Compliance with the exercise
program
2
Self-report and objective measures (e.g. attendance, exercise logs, target intensity); intervention arm only.
1 assessment at T = 0 only
2 assessment at T = 1 only
3 assessment at T = 0, T = 2
4 monthly assessments between T = 0 and T = 1 and once every 3 months between T = 1 and T = 2
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T h eE X I S Ts t u d yw i l la s s e s st h ee f f e c t i v e n e s so fah i g h
intensity strength and interval training program on phy-
siological and psychological variables in patients with
MM, NHL or HL who have recently undergone HDC
followed by ASCT. In addition the cost-effectiveness of
the program will be determined.
This study has several strengths. Firstly, the trial
design is solid; we will conduct a randomised controlled
trial among well defined patient groups, using standar-
dized outcome measures, and including a long term fol-
low up to assess the therapeutic sustainability of the
program. Secondly, the exercise program is developed
based on existing evidence and consists of both strength
and endurance exercise. Therefore, the exercise program
is considered to have a higher potential to restore mus-
cle mass compared to an endurance exercise program
alone, and consequently, we expect an improvement in
the physical as well as the psychological health status of
ASCT patients. Furthermore, counselling sessions are
included to increase motivation and compliance to phy-
sical exercise both during and after completion of the
intervention. Thirdly, a cost-effectiveness evaluation will
give insight in the costs of the program with respect tot
the outcomes.
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